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1
2, 4-DISULFONYL PHENYL BUTYL
NITRONE, ITS SALTS, AND THEIR USE AS
PHARMACEUTICALS

or Z; or
0
—CH=N+

BACKGROUND OF THE INVENTION

Y

This is a divisional of application Ser. No. 08/426,961
?led on Apr. 24, 1995, now U.S. Pat. No. 5,475,032 which
is a CIP of Ser. No. 173,579, ?led Dec. 23, 1993, now U.S.
Pat. No. 5,488,145.
This invention relates to a particular nitrone compound
and its salts and their advantageous use as pharmaceutical

and n is a whole integer from 1 to 5 or

nitrone free radical trapping agents.
and Y is tert-butyl or a hydroxylated or acetylated tert
butyl or a substituted phenyl. These compounds were
proposed as pharmaceutical agents to treat the after
math of stroke and other conditions reported to be

BACKGROUND INFORMATION

Alpha-phenyl tert butyl nitrone
0

(

20

C={I‘I—C(CHa)s)

or “PBN”) was identi?ed in the 1970s as a useful analytical

reagent to be used in conjunction with electron spin reso
nance (“ESR”) to aid in the detection of free radicals. PBN

25

associated with free radical damage.
In 1992 a second PCT patent application was ?led
directed to PBN and related compounds and their medical
use. This application, based on prior U.S. patent application
Ser. No. 716,952 (?led Jun. 18, 1991 abandoned on Apr. 26,
1993), was published on Dec. 23, 1992 as WO 92/22290.

This 1992 publication provided two extremely broad and
general disclosures. First, it attempted to describe as many

was found to react with certain free radicals and generate a

disease states as possible which were associated with free
radicals. These ranged from CNS conditions (including
thus making it possible to determine the presence or absence
30
stroke, aging, migraine, etc.) through peripheral organ dis
of free radicals.
ease (including atherosclerosis, bed sores, wounds, and
In the late 1970s and early 1980s the medical community
began to focus on the roles played by free radicals in
muscle overexertion) through UV exposure, to mention but
diseases such as heart attacks, strokes and the like. PBN was
a few highlights. Second, it attempted to list as many

chemical species yielding a characteristic ESR spectrum and

used increasingly in vitro to provide analytical evidence of
the presence of free radicals in these settings. It was also
later administered in vivo in animal models, again as an

35

potential spin traps as possible.
In addition to a whole range of non-PBN materials, this

application greatly expanded the de?nition of potentially

analytical adjunct in attempts to observe free radicals during

useful PBN compounds to include PBN, and derivatives

ischemia simulations and the like.

thereof of the formula

In the mid 1980s, the ?rst possible therapeutic e?’ects of
PBN were implied when severe trauma ischemia animal
tests showed that PBN-treated animals were more likely to

40

H

O

survive than controls.

On May 2, 1991, PCT patent application WO-9l-05552
was published. This patent application, which in part cor
responds to now-issued U.S. Pat. Nos. 5,825,032 and 5,036,
097, described PBN and a family of PBN derivatives de?ned
by the formula
H

45

wherein

X is phenyl, imidazolyl, phenothiazinyl or
(112)"

0

50
C=N+
X

Y

wherein
X is phenyl or

n=1—5, preferably 1-3;
Rzq'ndependently (can vary within the molecule) halo

gen, alkyl, oxyalkyl, alkenyl, oxyalkenyl, OH, NHZ,
NHZ, N22, NO,

(0K)"
60

where R is H,
0

ll
Z—C—

65
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Accordingly, in one aspect, the invention provides the

-continued

PBN-disulfonyl compound

A

ll

O_

l

—SO3H, —OSO3H, SH, —S(alkyl), —S(alkenyl), and
haloalkyl, speci?cally including -—CF3;
A=O or S; and

Z is a C1 to C6 straight, branched, alkyl or cyclic group;
10

and

and its pharmaceutically acceptable salts.
In a second aspect, the invention provides parenterally-,

Y is a tert-butyl group that can be hydroxylated or
acetylated at one or more positions; phenyl or

e.g. intravenously- and orally-administrable pharmaceutical
compositions having this compound or its salt as active

ingredient.

(112)"
15

In a third aspect, this invention provides a method for

treating a patient who is suffering from a condition involving
acute oxidative damage to the central nervous system, such
as a patient who has suffered a stroke, in which a pharma
ceutical composition based on this compound or its salt is

PBN was stated to be the most preferred compound at that
time, being said to have no measurable eifect on normal or 20 administered parenterally, e.g. intravenously.
In a fourth aspect, this invention provides a method for
uninjured cells, and a number of derivatives were also stated

to be useful, including hydroxy derivatives, especially 2-, 3
or 4-hydroxyphenyl t-butyl nitrone and phenyl (mono-, di
or trihydroxy) tert-butyl nitrone; PBN esters, especially
esters which release 2-, 3-, or 4-hydroxyphenyl t-butyl
nitrone such as acetoxy derivative; 2-, 3-, or 4-carboxyphe

25

treating a patient su?ering from a condition characterized by
protracted low grade oxidative stress upon the central ner
vous system and progressive loss of central nervous system
function. In this method, a pharmaceutical composition
based on this compound or its salt is administered parenter

nyl t-butyl nitrone; phenyl hydroxybutyl nitrone; alkoxyl

ally, e.g. intravenously or preferably orally.

derivatives, especially alkoxyl derivatives which release 2-,
3-, or 4-hydroxyphenyl t-butyl nitrone, for example, the 2-,

reducing or ameliorating the side-effects arising from oxi
dative damage produced in a patient by cancer therapy. In
this method a pharmaceutical composition based on this
compound or its salt is administered parenterally, e. g. intra
venously or orally.

3-, or 4-methoxyphenyl derivatives of PBN; and acetamide
derivatives, especially acetamide derivatives which release

In a ?fth aspect, this invention provides a method for
30

2-, 3-, or 4-aminophenyl t-butyl nitrone; diphenyl nitrone
(PPN) and the analogous diphenyl nitrone derivatives;

N-tert-butyl-ot-(4-nitrophenyl) nitrone; and N-tert-butyl-ot
(2-sulfophenyl) nitrone.

35

DETAILED DESCRIPTION OF THE
INVENTION

This Detailed Description is arranged into the following
sections:

STATEMENT OF THE INVENTION
40

It has now been discovered that one particular PBN

Brief Description of Drawings.
The Compounds and Salts.

derivative and its salts have unexpectedly superior pharma

cological properties. Although this derivative, 2,4-disulf0nyl

Compound Preparation.

PBN, falls within the broad family of materials generally
described in the aforementioned WO 92/022290 publication,

Pharmaceutical Compositions.

it is not speci?cally disclosed. Neither are its advantageous

45

Conditions Treated and Treatment Regimens.

Examples.

properties predicted.
The present compound with its two sulfonate groups was
BRIEF DESCRIPTION OF THE DRAWINGS
expected to exhibit improved water solubility but was also
50
In this speci?cation reference will be made to the accom
expected to exhibit poor transport across the blood/brain
panying drawings in which
barrier because of its lipophobic character. However, when
FIG. 1 is a schematic ?ow chart of the reactions used to
the present compound was made and tested in vivo, it
prepare the compound.
showed an unexpected increase in e?icacy as compared to
PBN. This increase in e?icacy occurred along with an 55
FIGS. 2 (A, B and C) and 3 (A, B, C, and D) are two sets
of graphs illustrating the undesirable change in animal body
increase in potency as compared to PBN. In direct contrast
thermal regulatory ability which occurs as a function of dose
to this marked increase in potency and e?icacy there was a
level with a prior art nitrone radical trapping agent and
marked and highly signi?cant decrease in toxicity as com
contrasting this with the lack of such undesired toxic effect
pared to PBN.
These results were unexpected because in the general 60 with the compound of the invention.
FIG. 4 (A, B, C, and D) is a set of four graphs demon
literature on structure/activity relationships within speci?c
strating the superiority of the compound of the invention as
de?ned families of compounds therapeutic potency typically
compared to a closely related prior art nitrone compound in
covaries with toxicity. Thus, most related compounds main
the treatment of gradual neurodegeneration conditions (such
tain their ratio of therapeutic potency to toxicity. In contrast,
the compound of this invention deviates from this expected 65 as Alzheimer’ 5 disease) as illustrated by their relative ability

relationship when its potency increased and its toxicity
decreased relative to closely related analogs.

to interfere with beta amyloid protein’s inactivation of key
enzymes in solution.

5,508,305
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In the second step, the freshly formed hydroxylamine is

FIG. 5 is a graph illustrating the effectiveness of the
compound of the invention in reducing the ultimate infarct
volume observed following middle cerebral artery occlusion

reacted with 4-formyl-l,3-benzenedisulfonic acid, typically

in rats.

can be carried out at similar temperature conditions. This

FIGS. 6 (A, B and C) are three graphs illustrating the
ability of the compound of the invention to reduce the
side-effects in animals of high dose levels of anticancer
agents.

reaction is generally complete in 10 to 24 hours.
The product so formed is the free acid and is characterized
by a molecular weight of 89 g/mole. It is a white powdery
material which decomposes upon heating. It is characterized
by a solubility in water of greater than 1 gram/ml and a 1H
NMR spectrum in D20 of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836
ppm (d, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s).
The various salts can be easily formed by admixing the
free acid in aqueous medium with two equivalents of the

THE COMPOUND AND SALTS

with a slight excess of the amine being used. This reaction

10

The compound of this invention is 2,4-disulfonyl ot-phe
nyl tertiary butyl nitrone. It is also referred to informally
herein as “2,4-disulfonyl PBN” or “PBN 2,4-disulfonate.” It
exists in an acid form

15

appropriate base, for example, KOH for the potassium salt,
and the like.

Pharmaceutical Compositions
20

The compound (including its salts) can be formulated into
pharmaceutical compositions suitable for oral or parenteral,
e. g. intravenous or intramuscular injection administration.
The compositions for oral administration can take the

as a solid and in solution in low pH conditions. It also exists
at higher pHs in an ionized salt form which can be shown as
25

form of liquid solutions or suspensions, powders, tablets,
capsules or the like. In such compositions, the PBN 2,4
disulfonate or its salt is usually a minor component (0.1 to

say 50% by weight) with the remainder being various
vehicles or carriers and processing aids helpful for forming
the desired dosing form. A liquid form may include a
suitable aqueous or nonaqueous vehicle with buffers, sus
30

pending dispensing agents, colorants, ?avors and the like.
A solid form may include, for example, any of the
following ingredients, or compounds of a similar nature: a

binder such as microcrystalline cellulose, gum tragacanth or
35

where X is a pharmaceutically acceptable cation. Most
commonly, this cation is a monovalent material such as
sodium, potassium or ammonium, but it can also be a
multivalent cation alone or in combination with a pharma

methyl salicylate, or orange ?avoring.

ceutically acceptable monovalent anion, for example cal
cium with a chloride, bromide, iodide, hydroxyl, nitrate,
sulfonate, acetate, tartrate, oxalate, succinate, palmoate or
the like anion; magnesium with such anions; zinc with such

gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel, or corn starch; a
lubricant such as magnesium stearate; a glidant such as
colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a ?avoring agent such as peppermint, sugar,

45

anions or the like. When these combinations of a polyvalent
cation and a monovalent anion are illustrated in structural
formulae, herein, the monovalent anion is identi?ed as “Y”.

In the case of injectable compositions, they are commonly
based upon injectable sterile saline or phosphate-buffered
saline or other injectable carriers known in the art. Again the
active nitrone is typically a minor component, often being
from about 0.05 to 10% by weight with the remainder being
the injectable carrier and the like.

Conditions Treated and Treatment Regimens

Among these materials, the free acid and the simple

case of the Zinc catalyst or an ether/water mixture in the case

The conditions treated with the 2,4-disulfonyl PBN gen
erally fall into three groups. The ?rst includes conditions
involving acute intense oxidative damage to a region of the
central nervous system. Examples of these conditions
include stroke, conditions associated with stroke, concus
sion and subarachnoid hemorrhage. In this setting, the
compound is administered in a manner designed to get the
drug into the patient’ s bloodstream as quickly and directly as
possible. This usually means intravenous administration.
Intravenous dose levels for treating these conditions range
from about 0.1 mg/kg/hour to at least 10 mg/kg/hour, all for
from about 1 to about 120 hours and especially 24 to 96
hours. A preloading bolus of from about 10 to about 500 mg
may also be administered to achieve adequate steady state
levels.
While intravenous administration is preferred, other
forms of parenteral administration, such as intramuscular

of the aluminum amalgam catalyst.

injection can be used, as well. In this case, similar dose

sodium, potassium or ammonium salts are most preferred 50

with the calcium and magnesium salts also being preferred
but somewhat less so.

Compound Preparation

55

As detailed in FIG. 1 and demonstrated in Example 1, the
compound of this invention can be prepared by a two step
reaction sequence. In the ?rst step, commercially available

tertiary butyl nitrate (2-methyl-2-nitropropane) is converted
to the corresponding n~hydroxyl amine using a suitable

60

catalyst such as an activated zinc/acetic acid catalyst or an

aluminum/mercury amalgam catalyst. This reaction can be
carried out in 0.5 to 12 hours and especially about 2 to 6
hours or so at a temperature of about 15° to 100° C. in a

liquid reaction medium such as alcohol/water mixture in the 65

5,508,305
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levels are employed. An unexpected and key advantage of

and the advantages of providing maximum possible protec

2,4-disulfonyl PBN is that it can be administered at vastly
higher levels than are possible with PBN itself. As will be
shown in the Examples, doses of up to 1000 mg/kg/hour and
higher or intravenous bolus doses of from 10 to 2500 mg/kg
have been demonstrated to be possible with 2,4-disulfonyl

tion or amelioration, it may be desired in some settings to
administer large amounts of 2,4-disulfonyl PBN such as
those described above for the acute intense oxidative CNS
damage conditions. In other settings lower doses, such as
those set forth for the progressive neuronal disease therapy,
may be used.

PBN or its salts while with PBN itself death or acute toxicity

results from such doses. With 2,4-disulfonyl PBN there is an

The following are examples of representative administra
tion regimens: In monotherapy (adriamycin alone) two

unexpected positive continuance of the dose/response curve

in these high dose levels with the clear message that intense 10
representative dose combinations are 10-600 mg Compound
heavy dosing immediately post stroke or other trauma may
I per square meter area plus 60 mg adriamycin per square
in many cases provide a major positive impact upon recov
meter of surface area with adriamycin dosing occurring
cry.
every seven or twenty-one days. Compound I may be
The second group of conditions which respond favorably
administered before the adriamycin, for example, up to 60
to 2,4-disulfonyl PBN treatment are conditions character
15 minutes before, at the same time or after, such as hours after
ized by protracted low grade oxidative stress upon the
and on subsequent days. The pediatric dose is typically
central nervous system and gradual progressive central
lower for both drugs. Higher doses may be used for treat
nervous system function loss. These conditions include
ment of multidose resistant tumors.

Alzheimer’s disease, Parkinson’s disease, arnyotrophic lat
eral sclerosis (ALS), multi-infarct dementia, retinopathy and
the like. Each of these conditions is characterized by a

EXAMPLES

progressive loss of function. 2,4-disulfonyl-PBN or its salts,
when administered orally or parenterally, e.g. intravenously,

Example 1

can slow and possibly reverse the loss of function. If

Synthesis

parenteral, e. g. intravenous administration is desired, similar

of

2,4-disulfonylphenyl-N-t-butylnitrone

levels to those used with acute conditions but at the lower 25 (Compound “I” in subsequent Examples). This preferred
synthesis is based on the work by R. H. Hinton and E. G.
end of the ranges are generally used.

Janzen (J. Org. Chem. 57:2646—2651, 1992). As shown in

- In these cases, the regimen for treatment may stretch over

FIG. 1 it involves the condensation of an aldehyde with a

many months or years so oral closing is preferred for patient
convenience and tolerance. With oral dosing, one to three

oral doses per day, each from about 0.02 to about 50 mg/kg
are called for with preferred doses being from about 0.04 to

hydroxylamine. The hydroxylamine is unstable and is pre
30

pared fresh on the day of use using an activated Zinc catalyst.
The synthesis is as follows:

about 5.0 mg/kg.

Prerequisite Chemicals

Of course, one can administer 2,4-disulfonyl PBN as the
sole active agent or one can administer it in combination
with other agents. This leads to a third application for this 35

compound.

plastic disease) therapy. The therapy which produces the

. 2-Methyl-2-nitropropane
. Zinc dust

A third set of conditions which respond to treatment with
2,4-disulfonyl PBN are the side-effects which arise in

patients from oxidative damage produced by cancer (neo

. 95% Ethanol

. Glacial acetic acid
. Diethyl ether
40

. Saturated sodium chloride

. Magnesium Sulfate, Anhydrous solid

oxidative damage (and thus the side elfects) includes radia
tion (e.g. gamma radiation) therapy and therapy with oxi

4-Formyl-1,3-benzenesulfonic acid (MW 310.21
g/mole), disodium salt, hydrate

dative-damage causing chemotherapeutic agents. Examples
of these agents include antibiotics such as daunorubicin,

9. Methanol
10. Dichloromethane

doxorubicin and bleomycin; procarbazine; nitrogen mus
tards such as ifosfarnide, melphalan and chlorambucil; alky
lating agents; antimetabolites; hormones and antagonists.

Procedure

Administration of 2,4-disulfonyl PBN can have the effect

of reducing patient discomfort during these therapies. In
addition, administration of the compound of this invention
can increasing patients’ ability to tolerate these therapies.
Often the side effects of therapies force the discontinuance
of these therapies or prevent the administration of optimal
high doses or rapid frequencies of these therapies. In some
cases these side effects are devastatingly destructive and
lead to heart failure and other major function loss. In tests in

animals it has been observed that the compound of the
invention can improve patient tolerance of these antine
oplastic disease treatments.
In this therapy, the compound of the invention may be
administered before, during and after the radiation or che
motherapy is administered. Administration may be
parenteral or oral or by any other method which will permit
the 2,4-disulfonate PBN to enter the patient’s bloodstream.

A positive dose-response relationship has been observed.
As such, and bearing in mind the severity of the side effects

50

55

A. Preparation of N-t-Butylhydroxylamine
1. A 500 ml three neck round bottom ?ask is equipped
with a magnetic stir bar, thermometer adapter, ther
mometer, and addition funnel.
2. 95% ethanol (350 ml) was added to the ?ask and cooled
to 10° C. in an ice bath.

60

3. 2-Methyl~2~nitropropane (6.18 g, 0.060 mole), and zinc
dust (5.89 g, 0.090 mole) were added in single portions.
4. Glacial acetic acid (10.8 g, 0.180 mole) was placed in
the addition funnel and added dropwise at such a rate

with vigorous stirring to maintain the temperature
below 15° C.
65

5. The ice bath was removed and mixture was stirred for
3 hrs at room temperature.

6. The solvent was stripped from the mixture, leaving
t-butylhydroxylamine, zinc acetate, and water.

5,508,305
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9

9. 4-Fonnyl~1,3-benzenesulfonic acid (MW 310.21

7. Dichloromethane (50 ml) was added and the mixture
?ltered through a Buchner funnel.

g/mole)

8. The zinc acetate cake left on the ?lter paper was washed

Procedure

with 2x25 ml dichloromethane.
9. Water was separated from the ?ltrate in a separatory

A. Preparation of N-t-Butylhydroxylamine

funnel and the organic layer dried over magnesium
1. Aluminum foil cylinders were dipped into HgCl2
solution for 15-30 seconds, then dipped in ethanol,

sulfate.

10. The magnesium sulfate was removed by ?ltering
through ?uted ?lter paper, then dichloromethane

then dipped in ether and then placed into a 5 l ?ask
containing 500 ml of diethyl ether and 21.4 ml of water.
2. The ?ask was ?tted with a 250 ml pressure-equalizing

stripped off by rotary evaporation.
11. The product (100% yield=5.34 g), a viscous liquid,

dropping funnel, a mechanical stirrer, a nitrogen inlet,

was dissolved in methanol (50 ml) for use in part B.

B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone

and a Friedrichs condenser cooled with recirculated ice
15

water.

3. The mixture was stirred for 10 minutes.

. A 3-neck 250 ml round bottom ?ask was set up with a

4. 2-Methyl~2~nitropropane (71.68 g, 75.5 ml) was added

stir bar, a gas dispersion tube, an addition funnel, and
a Friedrichs condenser cooled with recirculating ice

using the dropping funnel at such a rate as to maintain
a vigorous reflux.
NOTE: Addition must be completed in less than 20 minutes

water.

_

or the yield drops signi?cantly.

2. To the ?ask were added 200 ml of methanol, 4-formyl

1,3-benzenedisulfonic acid (9.31 g, 30 mmoles) and
N-t-butylhydroxylamine (25 ml of the methanol solu
tion from part A, 30 moles theoretical).

5. As the addition proceeded, ether was added in 500 ml
portions. This was done to maintain as high a concen

tration of product as possible without the formation of

3. The reaction was heated to re?ux with a heating mantle 25

while bubbling the reaction with nitrogen with stirring.
4. The mixture was re?uxed for 2 hours.

5. The remainder of hydroxylamine from part A was
added.
6. Re?uxing was continued with nitrogen bubbling for at
least 18 hours, but not more than 24 hours.

30

batches to remove aluminum salts.

8. Each ?lter cake was washed with l of ether.
9. The combined either layers were washed with 300 ml

7. The hot reaction mixture was ?ltered on a Buchner

funnel, and the solid washed with hot methanol.

8. The methanol was stripped off by rotary evaporation to
a yellow, viscous oil.

35

of 2M NaOH, then dried (MgSO4), and concentrated in
vacuo to leave a soft white solid.

'

10. The solid melts just above room temperature, but

9. Hot 1:1 ethanolzacetone (200 ml) was added and the

could be dried further in a vacuum oven (no more than

mixture heated to dissolve the oil.

10. The solution was cooled to crystallize the product.

a few minutes), leaving 38 to 45 g of solid.
40

11. The product was collected on a Buchner funnel and
dried under vacuum overnight.

11. The solid can be used as is or was puri?ed by

recrystallization from pentane.
12. Molecular weight—89 g/mole.
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone

12. The reaction typically gives 75% yield of Compound
I, a white powder.

a gel. Up to 2 l of ether can be added with no deleterious

e?ects on the yield.
6. Once addition of 2-methyl-2-nitropropane was com
plete, the reaction was stirred for an additional 30
minutes.
7. The resulting gray suspension was suction ?ltered in 3

‘
45

1. A 250 m1 ?ask was equipped with a stir bar and a
Fn'edn'chs condenser cooled with recirculated ice

Example 2
Alternate Synthesis of 2,4-disulfonylphenyl-N-t-butylni

water.

trone (Compound I). This is an earlier-developed method
which used to prepare samples of the compound used in
several of the experiments reported in the Examples of this
speci?cation. The product of this Example is identical in all
ways to the product of Example 1. This synthesis method is

2. The ?ask was charged with 71.8 ml of methanol, 14.5

g of 4-formyl~1,3-benzenedisulfonic acid (46.7
mmoles, 1 eq.), and 5.0 g of N-t~butylhydroxylamine

(56.2 mmoles, 1.2 eq.).
. The mixture was re?uxed overnight.

as follows:

4. The reaction product was transferred to round-bottom
55

Prerequisite Chemicals
1. Aluminum Foil, cut into 5 cm wide strips and rolled in
a ca. 1 cm diameter cylinder

. Mercury (ll) Chloride (9.68 g in 476 ml water)

60

insoluble precipitates and recrystallized twice from

. Ether (6 l)

methanol.

. Pure Water

. Sodium Hydroxide, 2M (80 g in 1 I water)
. Magnesium Sulfate, Anhydrous solid

decanted o?' (yellow).
6. Step 5 was repeated.
7. Product (“Compound I”) was crystallized from metha
nol following a hot methanol ?ltration to remove

. Ethanol

. 2-Methyl-2-nitropropane

?ask and rotovaped to dry.
5. The solid residue was mashed with ether, the ether was

) Example 3
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A series of experiments were carried out to compare in

vivo the e?icacy of 2,4 disulfonyl PBN (“Compound I”),

5,508,305
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PBN, and two monosulfonate PBN compounds as agents for
protecting against neuron loss following brain ischemia and

TABLE 2

reperfusion injury. The test procedure is that reported by W.

Neuronal nuclei/100 micron ?eld

Cao, J. M. Carney, A. Duchon, R. A. Floyd and M. Chevion
as “Oxygen free radical involvement in ischemia and rep
erfusion injury to brain, Neuroscience Letters, 88 (1988),
233. In the experiments a test compound was administered
to groups of six gerbils i.p. as a single dose 30 min before
5 min bilateral carotid occlusion. The density of neuronal

PBN

Non—ischemic control

Ischernic control
10

nuclei in a 100 micron was measured. Two controls were

32 mglkg

present-controls which received no test compound and

50 mg/kg

3

Cmpd.

sulfo

I

4.18

4.18

4.18

4.18

(.59)

(.59)

(.59)

(.59)

0.85

0.85

0.85

0.85

(.19)

(.19)

(.19)

(.19)

1.09

ND

ND

(.31)

controls which received no test compound and no brain
100 mg/kg

ischemia. As illustrated in Table 1. the compound of the
invention showed unexpected advantages as compared to the
prior art compounds. First, it is seen that at low dose levels,
such as 3.2 mg/kg, compound I is 2—3 times as potent at
preventing neuronal loss. At high dose levels it is seen that

Compound I is able to achieve complete protection against

2sulfo

320 mg/kg
1000 mg/kg

1.83

(.41)

1.85

0.68

0.73

2.73

(.49)

(.31)

(.34)

(.39)

2.11

0.78

1.09

3.41

(.51)

(.23)

(.48)

(.37)

0.93

2.25

0.81

(.43)

(.31)

Toxic

ND

3.55

(.48)
ND

3.68

(39)
20

neuronal loss as the test brains showed neuronal densities
identical to the non-ischemic controls. The prior art com
pounds are either toxic at these dose levels or showed

Example 5
Compound I is compared with PBN to determine the

signi?cantly lower degrees of protection. These results show

a clear increase in potency for neural protection for com 25 relative eifectiveness for protection of neuronal loss when

administered i.v. 60 min after reperfusion onset following 5
min ischemia in gerbils using the general test method

pound I compared to PBN and two closely related analogs
and an unexpected decrease in toxicity compared to PBN.

described in Example 1. The results are summarized in Table
TABLE 1
30

Neuronal nuclei/100 micron ?eld

Non-ischemic control
Ischemic control

3.2 rug/kg

10 mg/kg

32 mg/kg
50 mg/kg

100 mg/kg

PBN

2sulfo

3sulfo

Cmpd.
I

4.21

4.21

4.21

4.21

(.43)

(.43)

(.43)

(.43)

0.58

0.58

0.58

0.58

(.28)

(.28)

(.28)

(.28)

0.43

0.73

0.35

1.43

(.18)

(.34)

(.21)

(.31)

1.13

0.68

0.81

2.57

(.39)

(.31)

(.40)

(.25)

1.83

0.73

1.63

3.53

(.21)

(.31)

(.35)

(.41)

3.11

1.01

1.63

4.11

(.29)

(.61)

(.35)

(.43)

3.68

0.93

1.93

4.18

(.71)

(.53)

(.39)

(.49)

320 mg/kg

3.78

1.11

1.78

4.23

(.43)

(.41)

(.40)

(.39)

1000 rug/kg

Toxic

0.98

1.58

4.11

(.43)

(.38)

(.41)

——

—

4.18

3200 mg/kg

Toxic

3. and illustrate that compound I is of signi?cantly greater
therapeutic bene?t in a clinical treatment setting following
injury to the brain.
TABLE 3

35

mg/kg single dose
0.0
Saline, no ischernia

4.11

0.5

1.0

10

—

—

_

_

__

_

(.28)
40

saline, ischemia

0.93

(.17)
PBN

—-

0.83

1.07

1.23

Compound 1

—
—

(.23)
1.25

(.29)
1.75

(.31)
2.43

(19)

(.28)

(.31)

N = 6 per group.

Neither PBN nor Compound I. had an effect on neuronal

density in control gerbils without brain injury.
50

Example 6
Brain injury can manifest itself as behavioral changes. In

Example 4
A series of experiments were conducted in which com
pound I was compared to PBN and two sulfonate analogs in

55

this experiment, young adult (3-4 months of age) gerbils
were tested to determine their ability to perform an 8-arrn
maze test 24 hours following an ischemic event as described

in Example 1. As compared to nonischemic animals, when

post-ischemia treatment. The general method described in

untreated they committed many more errors. PBN and
tered i.p. as a single dose 30 min after reperfusion following 60 compound I were administered to some of the test animals.
As detailed in Table 4. gerbils treated with high doses of
5 min ischemia. The results are summarized in Table 2.

example 1 was used but the test compounds were adminis

Table 2 shows that the compound of the invention is again

compound I had error levels indistinguishable from those of

more potent at low doses and more potent and less toxic at

nonischemic animals. PBN was less effective. This shows

high doses. Also again, toxicity interferes with the ability of
the prior art compounds to go to high doses at which levels

the compound of the invention provides dramatically effec
tive therapy.

65

that compound I can protect against the loss of temporal/
spatial short term memory following ischemia (24 hours
post) errors in 8-arm radial maze test of young gerbils

following 5 min ischemia.

5,508,305
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TABLE 4

. TABLE 7

mg/kg/hr for 24 hours
0.0
Control

1.0

4.1

32

-——

Ins/kg

50

——

100

5

-—

(.38)
Postischemic

37.6

—

——

% Survival

320

n = 20 mice
PBN

560

1000

3000

10000

100

25

0

O

0

Compound I

100

100

100

100

.100

~

(4.85)
PBN

-

>
Compound I

—

29.8

18.19

6.23

5.83

(7.27)

(5.83)

(.71)

(.49)

14.63

7.19

4.28

4.11

(3.81)

(.81)

(.29)

(.19)

N=6Per gT‘mP‘

10

Example 10

Another undesirable systemic effect which has been
observed in vivo with nitrone radical traps is a depression in
body temperature. This toxicity can have serious health
15 consequences and also can complicate diagnosis of other
conditions. As detailed in FIGS. 2 and 4, the compound of

Example 7

this invention was administered to mice and gerbils at levels

. .

.

.

as high as 1000 mg/kg with no measurable temperature

.nfThi abihty zf?he (.mmpoimg of.the m‘tlennog :0 ref“?
1 are ‘:0 mile 0 owmg anlsc emlc even was. s ermine ‘

decrease. In contrast, the compound of the art, PBN, gave up
to an 8° C. decrease in body temperature at a does of only

20
As detailed in Table 5. it was observed that while PBN and
500 mg/kg
compound I were both effective at low doses, at high doses
'
I gave the best protection and PBN was toxic. Table 5 shows
Example 11
the infarct volume observed when test compound was
administered iv. 60 min after middle cerebral occlusion and 25
The compound of the invention was tested to determine
continued for 24 hours in C57BL/6] mice.
its effectiveness in the treatment of conditions characterized

by protracted low grade oxidative stress upon the central
TABLE 5
Infarct volume in m3
Posttreatment
(mgfkglhr) _

0.0

nervous system and gradual progressive central nervous
system function loss by testing its effectiveness in a model
30 for Alzheimer’s disease (“AD”). This model has the follow

1.0

10

100

ing basis: Recent studies have demonstrated that there is an
age-associated increase in protein oxidation and loss of

:

:

:

enzyme activities in the brain of aged individuals. Tissue

13.8

Toxic

_

(sjgi‘r‘lmislzgglcigema

2g

’

(2)

cultures of ?broblasts from aged individuals and red blood

PBN

-

17.7

35 cells of different ages both show an exponential increase in

(2.8)

(2.3)

Cmpwndl

_

16's

12'7

8'3

and a decrease in marker enzyme activities. Brain protein

(1.7)

(3.93)

(.71)

oxidation progresslvely mcreases over the life span of the
individual.

protein carbonyl content (a measure of protein oxidation)
.

40

.

.

.

.

In this study, compound I and PBN are compared for their

The role of abnormal amyloid precursor peptide process
ing and metabolism in AD has also been explored in a
number of different models. In vitro studies using embryonic
hippocampal neuronal and neuronal/glial cultures have dem

ability to impart lethality Protection (% Survived) in aged

onstrated that BAP l-40 produces cytotoxicity over an

Example 8

gerbils (18-24 months of age, n=12/gr011p) from 10 min 45 extended period of co-incubation. When this peptide is
ischemia when given 30 min before ischemia- AS Shown in
infused into rat brains, lesions are produced. Some of the
Table 6. compound I is superior at all dose levels and
proposed breakdown fragments of BAP are also neurotoxic
achieved complete protection at high levels while PBN is
[@g, BAP (25-35)]. The neumtoxicity appears to be both

only partially eifec?v?-

mediated via glutamate receptors, and also by non-glutamate
50 receptors mechanisms. Confocal microscopy studies of neu
ronal cultures have demonstrated that exposure to BAP

TABLE 6
Pretreatment

Q0

10

32

100

320

(l-40) results in oxidative stress [Dichloro?uorescein and

(mg/kg)

increased intracellular free calcium Fura-Z].
*

“

PBN

Saline
_

42

50

75

92

compoundl

_

5o

75

100

_

100

_

It has been demonstrated that BAP fragments can directly
.

.

.

.

.

55 inactivate glutannne synthetase (GS) and creatme kmase

(CK) in tissue extracts and in cultured hippocampal neurons
and glia (See A and B in FIG. 4). A and B of FIG. 4 present

the dose-related inactivation of glutamine synthetase and

Example 9

creatine kinase by AP (25-35). Cytosolic fractions from
60 gerbil neocortex were prepared and enzyme activities deter

An important advantage of the compound of this invention as compared to the art-taught compound, PBN, is its
markedly diminished toxicity. As detailed in Table 7. acute
lethality in C57BL/6L mice was determined based upon
varying sizes of single i.p. doses of nitrone. PBN showed 65

signi?cant toxicity at 560 mg/kg dose levels. Compound I

mined. Samples were incubated in the presence of different
concentrations of the peptide for 10 min prior to assay. Solid
symbols represent the effects of the naturally occurring
25-35 fragment. Open circles indicate that the reverse
sequence (32-25) had no effect on enzyme activity. Open
triangles indicate that the scrambled amino acid sequence

showed no toxicity at doses nearly twenty times as great.

also had no effect on enzyme activities, compared to the

5,508,305
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Adriamycin Studies

eifect of 25-35. Each point is the mean (ise) of 5 obser
vations. BAP derived and other cellular sources of free

Adriamycin is a widely used anticancer agent. It is known‘

radicals are an important determinant of the initiation and

to be very effective but it is also known to have serious side

progression of AD.
As demonstrated in C and D in FIG. 4, compound I and
PBN each show the ability to protect GS and CK against the
effects of [SAP fragments. C and D of FIG. 4 present the
protective effects of co-incubation of the cytosolic fractions
with BAP 25-35 (0.4 mg/ml) in combination with different
concentrations of PBN (open circles) or compound I (closed

eifects arising from its tendency to cause oxidative damage.
These side effects include causing serious levels of cardiac
damage at high dose levels. These side effects have often

circles). Each point is the mean (ise) of 3 observations. As
can be seen in C and D, compound I gives complete
protection and in fact might even be able to reverse the
effects of oxidation. In contrast, PBN’s effectiveness is quite
limited as it is asymptotically leveling out at a substantially

limited the use of this agent or limited the dose levels that
can be employed to levels which are below those desired for

maximum antineoplastic disease effectiveness.
10

Experiments were carried out to demonstrate that the

compound of the invention is effective at reducing the side
eifects of anticancer agents such as adriamycin and permit

ting higher dose levels of adriamycin to be tolerated by
15

incomplete level of protection.

animals.
C57BL/6J and DBA/2J male mice (35—40 g) were tested
for the acute lethal effects of adriamycin and the prevention

of acute lethality by pretreatment doses of Compound I.
Mice were injected with either saline or Compound I 30

Example 12

minutes prior to administration of adriamycin. All injections
were intraperitoneal. The acute lethality of adriamycin
ranged from 10 to 30 mg/kg. The LD5O for adriamycin in

Experiments were carried out to further demonstrate the

effectiveness of the compound of the invention in preventing
central nervous system damage caused by stroke.
Rat Focal Ischemia Results
A pair of studies were done to determine the e?icacy of

these tests was found to be 25 mg/kg in both mouse strains.

Compound I doses up to 300 mg/kg, without adriamycin
treatment, had no effect on survival in the two mouse strains.
25

Pretreatment with 30 and 100 mg/kg of Compound I
produced dose related shifts in the adriamycin lethality dose

Compound I in a rat focal ischemia model. In this model,

Sprague Dawley rats (200—300 g) underwent a permanent
effect curve. FIG. 6 shows the results obtained using the
middle cerebral artery occlusion (MCAO) to induce a focal
DBA/2J mouse. A dose of 100 mg/kg of Compound I
stroke. Compound I was administered after the permanent
30 produced a 5-fold shift to the right (in the direction of
occlusion as ?rst an intraperitoneal (i.p.) bolus dose and then
reduced lethality). Thus, the combination of Compound I
by intravenous (i.v.) continuous infusion during the remain
with adriamycin resulted in a marked increase in the maxi
ing time up to 24 hours post stroke. The doses of Compound
mally tolerated dose. These higher doses are in the range that

I used were either 100 mg/kg, i.p., followed by 4.2 mg/kg/hr,
i.v., or 10 mg/kg, i.p., followed by 0.42 mg/kg/hr, iv.

The rats were sacri?ced 3 days post stroke, the tissue was

35

processed histologically using triphenyltetrazolium staining
techniques, and the infarct volume, the area of total cell

necrosis, was quantitated using image analysis. The results

would effectively kill multi-drug resistant tumors.
Comparative Tests
PBN pretreatment resulted in a slight shift to the right in
the adriamycin does-effect curve. While the Compound I
dose could be increased to 300 mg/kg in combination with

of these experiments are shown graphically in FIG. 5 and 40 adriamycin, there was an upper limit for this combination
with PBN. A dose of PBN of 100 mg/kg produced slight
demonstrate that Compound I provided signi?cant protec
sedation and 300 mg/kg yielded marked sedation and some
tions, approximately 70% in both studies.
combined toxicity (l0—20% lethality). Compound I/adria‘
Comparison with Results in the Literature
mycin did not produce any combined toxicity at doses of
Similar data have been reported recently for the com
Compound I of up to 300 mg/kg.

pound NOT of this invention, PBN, by Cao and Phillis
(Brain Research 664: 267-272, 1994). In their studies, rats
underwent a permanent middle cerebral artery occlusion
(MCAO) and a common carotid artery occlusion. The PBN
was administered i.p. at 100 mg/kg at various times post
stroke. The rats were sacri?ced 2 days post stroke and the

45

Example 14

Safety Testing
Compound I and PBN were tested for their acute toxicity
50

infarct volume was quantitated using triphenyltetrazolium

in male Sprague Dawley (200—300 g) rats. The compounds

hours post stroke, or at 5, 17, 29, and 41 hours post stroke,

were administered at 1000 mg/kg, i.p., to groups of 6 rats.
After 3 days lethality was assessed. Compound I caused no
lethality, while PBN was lethal to 5 of the 6 rats used in this
test. These data con?rm the gerbil data in that Compound I

of Compound I required for 70% protection. Thus, Com;

patient by oxidative damage producing antineoplastic dis

stain.
When PBN was administered at 0.5, 5, 17, 29 and 41

the infarct volume was reduced in each case by approxi 55 has higher safety than PBN.
What is claimed is:
mately 50%. The cumulative dose of PBN administered to
1. A method for ameliorating the side effects caused in a
achieve 50% protection is at a minimum 4 times the amount

pound I is far superior to PBN in offering protection in the
rat MCAO focal ischemia model.

60

ease treatment, comprising administering to said patient an
elfective side e?ect-ameliorating amount of a pharmaceuti

cal composition comprising the compound 2,4»disulfonyl
ot-phenyl tertiary butyl nitrone in a pharrnaceutically accept
able carrier.
2. The method of claim 1 wherein the composition is

Example 13
In this Example the compound of this invention (Com
pound I) was evaluated to determine its ability to ameliorate
oxidation-caused side effects of anticancer therapy.

65

administered parenterally.
3. The method of claim 2 wherein the composition is

administered intravenously.

5,508,305
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10. The method of claim 9 wherein the composition is

4. The method of claim 1 wherein the composition is

administered orally.

admixed parenterally.

5. A method for ameliorating the side effects caused in a

11. The method of claim 10 wherein the composition is

patient by oxidative damage producing antineoplastic dis
ease treatment, comprising administering to said patient an
effective side e?ect ameliorating amount of a pharmaceuti

administered intravenously.

cal composition comprising a compound of the formula

administered orally.

12. The method of claim 9 wherein the composition is
13. A method for ameliorating the side eifects caused in

0.
10

a patient by oxidative damage producing antineoplastic
disease treatment, comprising administering to said patient
an eifective side e?'ect-ameliorating amount of a pharma

ceutical composition comprising a compound of the formula
in a pharrnaceutically acceptable carrier.
6. The method of claim 5 wherein the composition is

15

administered parenterally.
7. The method of claim 6 wherein the composition is

administered intravenously.
8. The method of claim 5 wherein the composition is

20

administered orally.
wherein X is selected from the group consisting of Na, K,
NH4, Ca Mg, Zn, ZnY, CaY and MgY, wherein Y is a
pharmaceutically acceptable monovalent anion, in a phar

9. A method for ameliorating the side effects caused in a

patient by oxidative damage producing antineoplastic dis
ease treatment, comprising administering to said patient an
effective side effect-ameliorating amount of a pharmaceuti

25

cal composition comprising a pharmaceutically acceptable

maceutically acceptable carrier.
14. The method of claim 13 wherein the composition is

salt of

administered parenterally.
15. The method of claim 14 wherein the composition is
30

administered intravenously.
16. The method of claim 13 wherein the composition is

administered orally.
in a pharmaceuticaily acceptable carrier.
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